Press Releases

May 13, 2020

Sanofi to showcase oncology portfolio and innovative pipeline at ASCO20 Virtual Scientific Program

- Emerging data demonstrate commitment to advancing cancer care, including two fully in-house investigational compounds: a potential best-in-class oral SERD for breast cancer and a first-in-class anti-CEACAM5 antibody-drug conjugate for non-small cell lung cancer
May 12, 2020

Sarclisa® (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma

- IKEMA trial results released early based on recommendation of an Independent Data Monitoring Committee
May 5, 2020

Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma

Objective responses seen in 29% of patients with locally advanced basal cell carcinoma (BCC)
Apr 27, 2020

Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival

- Libtayo decreased the risk of death by 32.4% compared to chemotherapy
Apr 27, 2020

Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients

• Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group

Show per page